In contrast to CHK2 protein-modifying mutations, the most frequent CHEK2 alteration c.319+43dupA (carried by 22% of NHL patients and associated with a decreased risk of NHL development) was significantly associated with better OS and PFS in DLBCL patients: HROS = 0.6 (P = 0.04) and HRPFS = 0.5 (P = 0.01; Fig 3C). This evidence concerns the gene CHEK2 and non-Hodgkin lymphoma.